Why pharma is a harder compliance problem
Pharmaceutical and API plants carry a compliance load that general manufacturing does not. The effluent is high-COD and chemically complex, solvents dominate the emission profile, product changeovers alter the waste stream several times a year, and everything has to be documented to a standard that survives both a pollution board inspection and a regulatory audit.
Effluent: the defining issue
API effluent typically arrives with high COD, high TDS and poor biodegradability - the combination biological treatment handles worst. Most API units in Maharashtra and Gujarat now operate under zero liquid discharge conditions, which means the ETP is only the front of a train that ends in evaporation and drying.
The practical difficulty is variability. A campaign-based plant does not produce one effluent - it produces a different one every few weeks, and a design based on an annual average will fail during the campaigns that matter.
Solvent emissions and occupational exposure
- Fugitive VOC emissions from reactors, centrifuges and solvent storage
- Process vents requiring scrubbing or condensation, and periodic stack monitoring
- Worker exposure to solvents, which needs a health risk assessment rather than area monitoring alone
- Solvent recovery, which is simultaneously an emission control and an economic recovery
Waste streams a pharma site has to account for
- Spent solvent and distillation residue
- ETP sludge and evaporation salt, both under hazardous waste authorisation
- Expired and rejected product requiring documented destruction
- Packaging under EPR
What we do for pharmaceutical clients
- Environmental clearance and EIA for new plants and expansions, including product-mix changes that trigger fresh appraisal
- MPCB and GPCB consents, amendments and renewals
- ETP and ZLD design, upgrade and troubleshooting
- Compliance audits and readiness reviews before an inspection
- HAZOP and QRA for solvent handling, hydrogenation and other high-hazard operations
- NABL accredited monitoring of air, water, effluent and workplace exposure
Frequently asked questions
A product-mix change is planned. Does that need fresh approval?
Usually yes. A change in products, or in the quantities of them, generally requires a consent amendment, and if it alters the pollution load materially it can require fresh environmental clearance. It is far cheaper to establish that before the change than after an inspection.
Our ETP fails whenever a particular campaign runs. What is going on?
Almost always shock loading. A campaign-based plant produces a different effluent every few weeks, and a biological stage sized on the annual average cannot absorb it. The fix is usually equalisation and segregation of the difficult stream, not a bigger ETP.
Do you work with USFDA or EU-GMP approved sites?
Yes. Those sites need environmental documentation that holds up alongside their quality systems - traceable, dated and defensible - which is how we prepare it regardless.
Is ZLD compulsory for pharma in Maharashtra?
Not by a blanket rule, but MPCB applies it widely to API and bulk drug units, and it is commonly written into consent conditions. Your own consent is the authority.